Morgan Stanley Knock-Out EVT/ DE000MG927Y3 /
11/13/2024 6:14:53 PM | Chg.- | Bid8:40:00 AM | Ask8:40:00 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
5.41EUR | - | 5.50 Bid Size: 2,500 |
5.67 Ask Size: 2,500 |
EVOTEC SE INH O.N. | 3.1614 EUR | 12/31/2078 | Call |
GlobeNewswire
12/11/2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune c...
GlobeNewswire
11/7/2023
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
GlobeNewswire
2/15/2018
EVOTEC AG AND MARS INNOVATION ANNOUNCE FIRST FUNDED PROJECT UNDER LAB150 BRIDGE
GlobeNewswire
1/8/2018
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi
GlobeNewswire
11/29/2011
Directors' dealings:Evotec AG:Director's Dealings announcement according to §15a WpHG (the German Se...
GlobeNewswire
10/27/2011
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi
GlobeNewswire
9/9/2011
Directors' dealings:Evotec AG:Director's Dealings announcement according to §15a WpHG (the German Se...
GlobeNewswire
9/5/2011
Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease
GlobeNewswire
9/5/2011
Evotec AG:Ad hoc:Evotec and Roche agree to develop compound that could slow the progression of Alzhe...
GlobeNewswire
8/18/2011
Evotec Receives Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer In...
GlobeNewswire
8/11/2011
Evotec reports 34% revenue and profitable earnings growth; revenue guidance raised
GlobeNewswire
8/11/2011
Evotec partners P2X7 antagonist programme, EVT 401, to a top tier global animal health company